Summit Therapeutics Inc (NAS:SMMT)
$ 18.21 -1.07 (-5.55%) Market Cap: 14.22 Bil Enterprise Value: 13.56 Bil PE Ratio: 0 PB Ratio: 32.46 GF Score: 29/100

Summit Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:45PM GMT
Release Date Price: $3.77 (-10.24%)
Natalie Collins
JPMorgan Chase & Co. - Analyst

Hi everyone, and welcome to the 41st Annual J.P. Morgan Healthcare Conference. My name is Natalie Collins, and I'm an associate in the J.P. Morgan healthcare investment banking team.

Just a reminder, we'll follow a 20-minute presentation format, followed by 20 minutes of Q&A. And with that, I'm thrilled to introduce the CEO, Bob Duggan; and co-CEO, Maky Zanganeh, of Summit Therapeutics.

Maky Zanganeh
Summit Therapeutics Inc. - Co-CEO & President

Thank you, Natalie.

(video playing)

Thank you, Shelley. Good afternoon. My name is Maky Zanganeh, the co-CEO at -- and President of Summit Therapeutics. I would like to thank J.P. Morgan team today, especially Mike Gaito, for inviting us to present our company, Summit Therapeutics.

These are forward-looking statements. We take no responsibility in updating any forward-looking statements that we will make in this presentation. I would like to start to give you an update about our Summit company.

Summit became a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot